EcoDrugPlus

Phosphoinositide-3-Kinase Regulatory Subunit 3

Ensembl ID : ENSMOCG00000009969
Gene Symbol: PIK3R3
3 Cross references
274 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 5

Ensembl ID : ENSMOCG00000012612
Gene Symbol: PIK3R5
3 Cross references
255 Possible Orthologues:

Phospholipase A2 Group Iia

Ensembl ID : ENSMOCG00000014091
Gene Symbol: PLA2G2A
2 Cross references
172 Possible Orthologues:

Phospholipase A2 Group V

Ensembl ID : ENSMOCG00000010173
Gene Symbol: PLA2G5
3 Cross references
116 Possible Orthologues:

Phospholipase A2 Group Vii

Ensembl ID : ENSMOCG00000000352
Gene Symbol: PLA2G7
3 Cross references
203 Possible Orthologues:

Phosphoribosylglycinamide Formyltransferase, Phosphoribosylglycinamide Synthetase, Phosphoribosylaminoimidazole Synthetase

Ensembl ID : ENSMOCG00000013615
Gene Symbol: GART
3 Cross references
215 Possible Orthologues:

Plasma Kallikrein

Ensembl ID : ENSMOCG00000019660
Gene Symbol: LOC101979791
3 Cross references
206 Possible Orthologues:

Plasminogen

Ensembl ID : ENSMOCG00000021058
Gene Symbol: PLG
3 Cross references
239 Possible Orthologues:

Plasminogen Activator, Tissue Type

Ensembl ID : ENSMOCG00000008549
Gene Symbol: PLAT
2 Cross references
204 Possible Orthologues:

Platelet Activating Factor Receptor

Ensembl ID : ENSMOCG00000013409
Gene Symbol: PTAFR
3 Cross references
224 Possible Orthologues:

Platelet Derived Growth Factor Receptor Alpha

Ensembl ID : ENSMOCG00000012103
Gene Symbol: PDGFRA
3 Cross references
204 Possible Orthologues:

Platelet Derived Growth Factor Receptor, Beta Polypeptide

Ensembl ID : ENSMOCG00000015349
Gene Symbol: PDGFRB
1 Cross references
247 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).